News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nuvilex Expects its Technology Can Start to Change Life for Diabetics


4/8/2013 9:33:17 AM

NEW YORK, NY--(Marketwired - April 08, 2013) - When Nuvilex, Inc. (OTCQB: NVLX) started its diabetes studies, it was likely well known then that while its late-stage pancreatic cancer trials are front and center, it is the company's work in diabetes that could put it on the map and really turn some heads.

The small Silver Spring, Maryland biotechnology company is already getting attention for its cell encapsulation technology's performance in its preclinical diabetes studies, and diabetics around the world surely have their fingers crossed that Nuvilex can continue to see such dramatic results.

At the end of 2012, statistics showed that 22.3 million Americans, or seven percent of the U.S. population, have diabetes. Last November, The International Diabetes Federation estimated that 366 million people were diagnosed with diabetes in 2011, and about another 180 million more are estimated as undiagnosed. That number is expected to climb to 552 million by 2030 if "urgent action" isn't taken -- that's 1 in every 10 people on the planet! Worse yet, those numbers are estimated to grow to 1 in every 3 people by 2050 at its current pace.

These numbers are mind-boggling and paint a clear picture of just how widespread the disease is. Most of us likely know someone who lives with diabetes, and that person very well could be you. With the dramatic rise in diagnosed cases of diabetes, more and more children are being added to the painful statistics.

This disease is everywhere and families from the east coast to the west coast and everywhere in between are affected. Whether it's 11-year old Devin Dunn in Fredericksburg, Virginia, or 20-year old Nick Cozzi in Joliet, Illinois or even 10-year old Austin Wikstrand in Kennewick, Washington, these young diabetics are part of a disturbing trend -- families that must learn a whole new way of life to live with the disease. All three suffer from Type-1 diabetes, and have had to make many adjustments in their lives just to survive.

Continue reading this article at www.stockhousegroup.com/features

About Stock House Group

Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. We offer a platform to CEOs to develop their story through articles, Research Reports, and CEO Interviews. Additionally, we're building a library for Investors to research small and large cap stocks.


Contact:
Stock House Group
www.stockhousegroup.com
Email Contact
646-397-4020

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


comments powered by Disqus
Nuvilex
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES